查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553451

免疫调节剂市场规模、份额、趋势分析报告：按解决方案、产品、应用、地区、细分市场预测，2024-2030

Immunomodulators Market Size, Share & Trends Analysis Report By Solution, By Product (Immunosuppressants, Immunostimulants), By Application (Oncology, Respiratory, HIV), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

免疫调节剂市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球免疫调节剂市场规模将达到3.298亿美元，2024年至2030年复合年增长率为6.2%。

预计该市场将主要受到知名公司采用的高研发投资的推动，从而导致新的治疗先进药物的大规模生产。因此，免疫调节剂市场预计将以前所未有的速度充斥药物，为许多自体免疫疾病和发炎疾病提供高效的治疗选择。

此外，预计抗药性的增加将增加开发具有标靶治疗机制的新一代免疫调节剂的临床紧迫性。上述因素的综合影响预计将在预测期内提供显着的成长机会。

此外，主要企业的快速成长预计不仅会提高患者而且还会提高医生对免疫调节剂效用的认识。预计这将在预测期内进一步扩大免疫调节剂产业的成长潜力。

此外，单株抗体越来越多地应用于多种适应症，如多发性硬化症、克隆氏症、类风湿性关节炎和非何杰金氏淋巴瘤，预计将在预测期内推动免疫调节剂业的发展。单株抗体在自体免疫疾病中具有重要意义，一致的产品核可数量预计将成为扩大成长范围的因素。

免疫调节剂市场报告亮点

  • 由于移植手术的增加以及防止器官排斥的需要，2023年免疫抑制剂在该产品类别中占据最大份额。
  • 由于肾臟、肝臟、心臟和肺移植的使用和收益增加，到 2023 年，抗体将占免疫抑制药物的压倒性份额。
  • 由于用于治疗爱滋病毒、癌症和多发性硬化症的学名药活化的流入减少，预计活化将出现高速增长。
  • 2023年，由于有大量参与大规模商业化的老牌製药公司，北美主导了全球免疫调节剂市场。
  • 领先的参与企业正在实施研究和临床合作策略，以创造新药并获得竞争优势。
  • 例如，2024年3月，Ability Biologics完成种子轮资金筹措，总投资额达1,800万美元。该资金将用于开发创新且高度针对性的免疫调节剂。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章全球免疫调节剂市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 全球免疫调节剂市场分析工具
    • 波特的分析
    • PESTEL分析

第四章全球免疫调节剂市场：按产品分類的估计和趋势分析

  • 细分仪表板
  • 全球免疫调节剂市场：2023 年和 2030 年产品变化分析
  • 免疫抑制剂
  • 免疫刺激剂

第五章全球免疫调节剂市场：按应用估计和趋势分析

  • 细分仪表板
  • 全球免疫调节剂市场：2023 年和 2030 年应用变化分析
  • 肿瘤学
  • 呼吸系统
  • HIV
  • 其他的

第六章 全球免疫调节剂市场：区域估计与趋势分析

  • 2023 年和 2030 年全球免疫调节剂市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc.
    • Abbott
    • Johnson &Johnson Services, Inc.
    • Novartis AG
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Merck &Co., Inc.
    • Biogen
    • Pfizer Inc.
简介目录
Product Code: GVR-1-68038-318-8

Immunomodulators Market Growth & Trends:

The global immunomodulators market size is expected to reach USD 329.8 million by 2030, expanding at a CAGR of 6.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to be predominantly driven by high R&D investments employed by prominent companies, resulting in the large-scale production of new and therapeutically advanced drugs. This is believed to widen the influx of drugs at an unprecedented rate into the immunomodulators market hence providing highly efficacious treatment alternatives for numerous autoimmune and inflammatory diseases.

In addition, increasing drug resistance is predicted to be responsible for boosting the clinical urgency to develop potentially new generation immunomodulators with targeted therapy mechanisms. The aforementioned factors cumulatively are expected to present significant growth opportunities over the forecast period.

Furthermore, the burgeoning presence of the key players is expected to promote the awareness levels pertaining to the benefits of immunomodulators amongst the patients as well as the physicians. This is further expected to widen the immunomodulators industry growth potential during the forecast period.

In addition, increasing adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn's disease, rheumatoid arthritis, and Non-Hodgkin's Lymphoma, which is expected to boost immunomodulators industry over the forecast period. The consistent number of product approvals of highly significant monoclonal antibodies in autoimmune diseases is predicted to be responsible for widening the scope of growth.

Immunomodulators Market Report Highlights:

  • Immunosuppressant held the largest share of the product segment in 2023, owing to the increasing number of transplantation procedures and need to prevent organ rejection
  • Antibodies held the dominant share of immunosuppressant in 2023, owing to extensive utilization in kidney, liver, heart, and lung transplants resulting in greater revenue generation
  • Immunostimulants expected to grow lucratively as a result of the lower influx of immunostimulant generics for application in HIV, cancer and multiple sclerosis
  • In 2023, North America dominated the global immunomodulators market owing to the presence of a wide number of established pharmaceutical companies involved in extensive commercialization
  • The prominent participants are undertaking research and clinical collaborative strategies to yield new drugs and thereby to gain competitive advantage
  • For instance, In March 2024, Ability Biologics concluded its seed funding, securing a total of USD 18 million in investment. This capital is expected to be directed towards the development of innovative and highly targeted immunomodulators.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Immunomodulators Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Immunomodulators Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Immunomodulators Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Immunomodulators Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Immunosuppressants
    • 4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immunostimulants
    • 4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Immunomodulators Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Immunomodulators Market: Applicaton Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Respiratory
    • 5.4.1. Respiratory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. HIV
    • 5.5.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Immunomodulators Market: Regional Estimates & Trend Analysis

  • 6.1. Global Immunomodulators Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. South Africa
      • 6.6.4.1. South Africa Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. F. Hoffmann-La Roche Ltd
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Amgen Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Abbott
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Johnson & Johnson Services, Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Novartis AG
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Eli Lilly and Company
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Bristol-Myers Squibb Company
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck & Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Biogen
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Pfizer Inc.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives